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SOLVENT SCREENING STUDY OF CARBAMAZEPINE CRYSTAL 
POLYMORPH 
 
 
ABSTRACT 
 
 
Realizing solvents can be paramount critical and important in crystallizing specific 
polymorphs, complete manual, references, method and approach in predicting the 
polymorph formed from the specific parameter need to be developed. Solvent screening 
is the process of determining the relation between solvent choose and respective crystal 
form mainly focused on the solubility and its related properties. For this particular 
research, the approaches is by choosing specific properties of solvent used to find the 
relationship between them to relate with the crystallize structure formed. Polarity, 
hydrogen-donor-acceptor, and dipole moment is known to give much effect on the 
polymorph formation. By selecting the solvent with distinct properties considering its 
polarity, hydrogen-donor-acceptor, and dipole moment, the carbamazepine will be 
dissolve and recrystallize. Gravimetric method was used to determine the solubility of 
carbamazepine. DSC and optical microscopes was used to characterize the polymorph. 
Van `t Hoff plot was constructed from the solubility data and the stability prediction was 
made based on the free energy value calculated. It is found that weak interaction of 
solvent-solute will result in more stable polymorph but not necessarily correct because 
other factor such as temperature need to be consider during dissolution and 
crystallization process. One solvent having a tendency to produce more than one type of 
polymorph depend on the temperature of dissolution. Morphology of carbamazepine 
polymorph inconsistent for several trials and can be change easily through the process. 
This result will be potential additional reference for more perfect approaches in the 
future especially for molecular dynamic simulation.  
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KAJIAN PENYARINGAN PELARUT PADA POLIMORF HABLUR 
KARBAMAZEPIN 
 
 
ABSTRAK 
 
Menyedari kepentingan pelarut dalam penghabluran polimorf tertentu, manual lengkap, 
rujukan, kaedah dan pendekatan dalam meramalkan polimorf yang terbentuk daripada 
parameter tertentu perlu dibangunkan. Penyaringan pelarut adalah proses menetukan 
kaitan antara pelarut yang dipilih dan hablur yang terhasil terutamanya tertumpu kepada 
kelarutan dan ciri-ciri yang berkaitan. Bagi tujuan penyelidikan ini, pendekatan yang 
diambil adalah memilih sifat tertentu pelarut yang digunakan dan dikaitkan dengan 
struktur hablur yang terbentuk. Kekutuban, penerima-penderma ikatan hidrogen, dan 
momen dwikutub adalah diketahui sangat memberi kesan kepada pembentukan polimorf. 
Dengan memilih pelarut dengan sifat-sifat yang berbeza seperti kekutuban, penderma-
penerima ikatan hidrogen, dan momen dwikutub, carbamazepine akan dilarutkan dan 
dihablurkan semuala. Kaedah gravimetrik telah digunakan untuk menentukan kelarutan 
carbamazepine. DSC dan mikroskop optik telah digunakan untuk menentubeza polimorf. 
Graf Van `Hoff telah dilukis daripada data kelarutan dan ramalan kestabilan telah dibuat 
berdasarkan nilai tenaga bebas yang dikira. Didapati bahawa interaksi yang lemah antra 
pelarut bahan larut akan menghasilkan polimorf lebih stabil namun tidak keseluruhanya 
diterima kerana faktor lain seperti ganguan suhu semasa pelarutan dan proses 
penghabluran perlu dipertimbangkan. Satu pelarut mempunyai kecenderungan untuk 
menghasilkan lebih daripada satu jenis polimorf bergantung kepada suhu pelarutan. 
Morfologi polimorf carbamazepine adalah tidak konsisten untuk beberapa cubaan 
penghabluran dan mudah sepanjang proses penghabluran. Dapatan kajian ini berpotensi 
sebagai rujukan tambahan untuk pendekatan yang lebih sempurna di masa hadapan 
terutamanya bagi simulasi dinamik molekul. 
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CHAPTER ONE 
 
 
INTRODUCTION 
 
 
1.1 Background of Proposed Study 
 
For decades, carbamazepine has served as a model compound for groups 
engaged in the study of crystal polymorphism, a very common phenomenon on 
pharmacological substance. Discovering a new polymorph is known to be time and 
resources consuming. A lot of trial and error need to be made if no complete or standard 
approaches for discovering new polymorph are establishes (Storey et al., 2004). Even 
there is no superior method or procedure, some distinguish feature or factor can be a 
guide to trial and error process. A lot of factor that can influence the formation of 
polymorph and one of the most important factors is solvent used. Solvent without failure 
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is essential remedies in pharmaceutical industry but wrong solvent will result in 
undesired polymorph. 
 
 
1.2 Problem Statement 
 
Determining the suitable solvent to be used in pharmaceutical industry are 
paramount important to avoid the formation of undesired polymorph. As one of the main 
factor, there is several sub-factor need to be consider related to solvent choose such as 
concentration, existence of water, supercritical condition, temperature, and so on 
(Morisette et al.,2004). It is often observed that a particular polymorph preferentially 
crystallizes from a specific solvent, especially when no seeds are present (Gidalevitz et 
al., 1997). Carbamazepine tends to presence in the four polymorphic forms because of 
solvent effect factor. Different polymorphs provide different desired properties for the 
drugs such as efficiency and bioavailability.  
 
 
1.3 Research Objectives 
 
The main objective of this research is mainly to determine the solubility of 
carbamazepine for the selected solvent to be correlated to the strength of molecular 
interaction and bonding with solute. Second objective is to determine the type of 
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polymorph after dissolving and recrystallization for the selected solvent. Third objective 
is to characterize the carbamazepine solid state properties polymorph using DSC and 
optical microscope.  
 
 
1.4 Research Questions/Hypothesis 
 
 High solubility of solute means there is strong interaction in the molecular level 
between carbamazepine and selected solvent. This is predicted to happen for polar 
solvent. Meanwhile for low solubility, it is predicted to happen for non-polar molecule, 
where there is weak interaction between the solvent-solute at molecular level. The 
crystal products can be easily being characterized through PXRD and DSC by compare 
it with the past study.  
 
 
1.5 Scope of Proposed Study 
 
The scopes of this study are focusing on the relation of solvent properties with 
the crystallization polymorph of carbamazepine. It studies the solute-solvent interaction 
and the inter-atomic distances between specified atoms on solute molecules by 
determine their time-solubility and the presence of H-bond in the crystal structure and 
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solutions. Solubility test are planned in room temperature of 27
o
C with the highest purity 
of solvent provide by the supplier. Gravimetric methods are used for as collecting 
method.  The characterization is commonly used PXRD and DSC, but as for further 
clarification, other equipment such as TGA and SEM also can be used.  
 
 
1.6 Expected Outcome 
 
It is believe that strong interaction between solute and solvent will result in weak 
bonding during the crystallization thus producing metastable polymorph during 
crystallization. This likely to happened for polar solvent. While weak interaction 
between solute and solvent will perhaps produce high stability polymorph of 
carbamazepine crystal that are likely to happen for non-polar solvent or solvent with low 
polarity. Non-polar solvent will give very low solubility that not preferable in 
pharmaceutical industry.  
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1.7 Significance of Proposed Study  
 
Determining the correct solvent to be used will bring great advantages to the 
pharmaceutical industry. The benefit is not only for carbamazepine production, the 
careful selection of solvent based on analysis of it characteristic can be helpful reference 
for determining solvent for other pharmacological compound. Moreover, the collected 
data can be used for simulation in the future. Use of simulation especially in 
pharmaceutical industry will help the researcher in doing the research in short time and 
low cost because they don’t have to set up the real experiment. 
 
 
1.8 Conclusion 
 
As a summary, realizing the important of understand the polymorphism, research 
to determine the specific properties toward the polymorph formation is indeed very 
relevant. Event it cannot find the superior approaches, at least it can be a valuable data 
for future references. By determining the molecular interaction of the solvent-solute, it is 
expected that it can be related to the stability of polymorph form. This study is not only 
focused on crystallization, but including understanding of theoretical approaches and 
most recent experimental method. 
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CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
2.0 Introduction 
 
The objective of this chapter is to extract and combine some of the finding in the 
past study that may relate to this research paper. As theory only is not enough for the 
research, there comes literature review as the supported information prior to the 
research. This chapter also will provide some data for comparison is discussion part. It 
will cover several main sub-chapters including polymorphism, short explanation on 
carbamazepine, polymorphism in carbamazepine, and solvent. 
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2.1 Polymorphism 
 
The ability of a compound to crystallize into more than one crystalline phase 
with different arrangement and conformation of the molecules in the lattice are called as 
polymorphism (Grant, 1999). In other word, it is a similar compound but with different 
crystal line. It is challenging enough for the manufactures and developers of such 
compounds since they exist in various solid-state forms, crystalline or amorphous 
(Morris et al., 2001). Polymorph known to give significant different in the 
physicochemical properties such as melting point, density, morphology, solubility and 
colour. It may affect the stability; physically or chemically, bioavailability and 
processability during production or in their final product form (Heinz et al., 2009). 
Worst case is undesired polymorph can be toxic (Knapman, 2000) that rise the concern 
to increase the regulatory requirement by Food and Drug Administration (Byrn et al., 
1995).  
 
Thermodynamically metastable forms are often desired in pharmaceutical 
development due to their enhanced biopharmaceutical properties, a result of higher 
solubility and faster dissolution rates. In different cases, metastable forms are not desired 
because of crystallization and transformation to a more thermodynamically stable form 
during processing, storage, or dissolution (Byrn et al., 1995; Shekunov and York, 2000). 
Recently, a multiple component crystal in which all components are solid under ambient 
conditions when in their pure form or called co-crystal have attracted interest in 
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pharmaceutical world as they offer an alternative way to overcome poor aqueous 
solubility without neglecting the stability ( Miroshnyk et al., 2009).  
 
Often, new polymorphs are discovered by trial-and-error by recrystallizing the 
compound of interest from various solvent. This is because no standard approach are 
developed in industry even realizing the importance of polymorphism and the need of 
solid-form screening for pharmaceutical related study (Getsoian et al, 2007). It is known 
that such factors as solubility, solvent viscosity, solvent polarity, evaporation rate, 
cooling rate, and initial solution concentration can affect the outcome of a crystallization 
but approaches to vary those factor are typically not systematic (Morissette et al., 2004; 
Hilfiker et al., 2006). Indeed, discovering new polymorphs is a time consuming and 
resource consuming process. Still, no polymorph screen can guarantee that all possible, 
or even pharmaceutically relevant, forms have been found regardless of the effort 
(Getsoian et al., 2007). 
 
 
2.1.1 Polymorphism of Active Pharmaceutical Ingredients (API) 
 
When a new API is launched on the market it is essential to have a thorough 
knowledge of its differing solid phases and to respect the Good Manufacturing Practice 
Guide for Active Pharmaceutical Ingredients (http://www.ich.org, 2012). Recent history 
in the pharmaceutical industry has shown that the emergence of a new phase can 
seriously compromise the intended process and potentially the patient’s life (Dunitz and 
Bernstein, 1995). Chemburkar, of Abbott laboratories, who dealt with the Ritonavir case 
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in the nineties, drew the following conclusion: ―Dealing with polymorphism is 
potentially precarious practice and the proper way to play this game is with patience and 
perseverance‖ (Chemburkar et al., 2000). 
 
 
2.2 Carbamazepine 
 
Carbamazepine is a chemical compound used in pharmaceutical for medicinal 
purpose, a first-line agent for localization-related epilepsy, and one of the most popular 
anticonvulsants used in children. Typically it has been used to treat seizure disorder and 
neuropathic pain. It may be used as a second line treatment for bipolar disorder and 
along with antipsychotic agents in schizophrenia. (The American Society of Health-
System Pharmacists, 2012) However, carbamazepine has some adverse effects like other 
antiepileptic drugs. Among the adverse effects of carbamazepine are drowsiness, 
vertigo, headache and ataxia have been reported as adverse neurotoxic effects (Gayford 
& Redpath, 1969) auditory disturbance associated with carbamazepine medication, such 
as hyperacousis and tinnitus, has been rarely reported (Tateno et al., 1993). 
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Figure 2.1 Chemical structure of carbamazepine (Grzesiak et al., 2003) 
 
 
 
Figure 2.2 More well illustrated chemical structure of carbamazepine. Grey molecules 
represent carbon, white molecules represent hydrogen, blue molecule represent oxygen, 
and red molecule represent nitrogen. (Wolfram Web Resources, 2012) 
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2.3 Carbamazepine Polymorph 
 
Carbamazepine (CBZ) is described as consisting of four polymorphs and as a 
dihydrate (Borka et al., 1992; Rustichelli et al., 2000). Form I or triclinic anhydrous 
(m.p. 190
o
C) and Form III or P-monoclinic (m.p. 177
o
C) is the commercial product, 
constitute an enantiotropic pair. Form III is the crystal form stable at ambient 
temperature up to 70
o
C, while Form I is stable above 70
o
C (Behme and Brooke, 1991). 
The trigonal and triclinic forms are monotropic (Edwards et al., 2001). The monoclinic 
polymorph is the most stable and least soluble of the anhydrous forms at room 
temperature while the trigonal is the least stable and most soluble form (Edwards et al., 
2001). The carbamazepine properties are summarized in Table 2.1. Three CBZ 
polymorph Form II-1V were found to transform to Form I upon heating (Grzesiak et 
al.,2003) from their respective form. 
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Table 2.1 Table of summarized properties of carbamazepine polymorph 
 
 Form I Form II Form III Form IV 
Morphology Needle 
(Grzesiak et 
al.,2003) 
-Various 
according  
method 
Needle 
(Grzesiak et 
al.,2003) 
-Various 
according to 
method 
-No previous 
report state 
clearly the 
correct 
morphology 
-Various 
according to 
method 
-No Previous 
report that state 
clearly the 
correct 
morphology 
-Various 
according to 
method 
 
Melting Point 
o
C 
(Grzesiak et 
al.,2003) 
-189 and 193 
°C 
-No 
transformation 
occurs during 
heating until 
melt 
-
Transformation 
occurs at 135
o
C 
and 170oC.  
-The new phase 
melted between 
188
o
C and 
192
o
C 
-Melts and 
crystallizes to a 
new form 
almost 
simultaneously 
between 162
o
C 
and 175 °C 
-The new form 
melts at 189 
and 193°C 
 
-Melts and 
partially 
crystallize to a 
new form 
between 178
o
C 
and 187°C 
Crystal 
structure 
(Grzesiak et 
al.,2003) 
triclinic 
anhydrous 
trigonal P-monoclinic c-monoclinic 
 
 
Grzesiak et al. (2003) arrange the stability of the four polymorph as: Form 
III>Form I>Form IV>Form II. This stability order is based on the density rule where 
higher density will give high stability. From the structure of the carbamazepine in Figure 
2.3-2.6, all four polymorph having identical anti-carboxamide dimer motif. This is 
significantly different to other highly polymorphic substance such as sulfapyridine, 
which display different conformation or strong hydrogen bonding pattern (Rodriguez-
Spong et al, 2004). From Figure 2.3 and Figure 2.4, the triclinic (Form I and Form II) 
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pack in a similar manner. Both structure form two C-H----O intermolecular interaction at 
benzenic hydrogen with oxygen of urea. However, in Form III and Form IV, the 
intermolecular interaction of double bond involve in azepine ring to the oxygen of the 
urea.  
 
 
 
Figure 2.3 Form I carbamazepine showing its hydrogen bond. (Rodriguez-Spong et al, 
2004) 
 
